CompletedPhase 4

Impact of Sugammadex vs. Neostigmine Reversal on Post-Operative Recovery and Complications

Canada120 participantsStarted 2019-01-14

Plain-language summary

Sugammadex or neostigmine are given at the end of the surgery to reverse neuro muscular blocking drugs (NMBD). This study will evaluate whether reversal of NMBD with sugammadex is associated with faster recovery than neostigmine resulting in faster discharge from the operating room (OR) in obese patients with OSA undergoing bariatric surgery. Half of the patients in the study will receive sugammadex and the other half of the patients will receive neostigmine.

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥ 18 years old * Diagnosed Obstructive Sleep Apnea patients by polysomnography * Scheduled elective bariatric surgery Exclusion Criteria: * Age\<18 years old * Allergy to rocuronium * Allergy to sugammadex * Allergy to neostigmine * Malignant hyperthermia * Hepatic insufficiency * Renal insufficiency * Neuromuscular Disease * Pregnancy

What they're measuring

Time to Discharge From Operating Room

Timeframe: 15 minutes

Trial details

NCT IDNCT03679611

SponsorUniversity Health Network, Toronto

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-10-26

Results submitted2024-09-23

View on ClinicalTrials.gov More Obstructive Sleep Apnea trials